Notably, combinatorial treatment with anti-VEGF therapy and anti-PD-L1 immunotherapy induces HEV formation and tumor infiltration of T cells, resulting in an enhanced anti-tumor immune response [87]. Here, VEGFA is linked to neoplasm.